Hidetaka Noma1, Tatsuya Mimura2, Kanako Yasuda1, Masahiko Shimura1. 1. Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan. 2. Department of Ophthalmology, Medical Center East, Tokyo Women's Medical University, Tokyo, Japan.
Abstract
BACKGROUND/AIMS: Correlations among functional-morphological parameters, the aqueous flare value (an indicator of inflammation) and aqueous humour levels of cytokines/inflammatory factors were investigated in patients with branch retinal vein occlusion (BRVO) and macular oedema who received intravitreal ranibizumab injection (IRI) and were followed for 6 months. METHODS: Aqueous humour levels of 11 cytokines or growth inflammatory/factors were measured in 45 patients with BRVO and macular oedema who received IRI. Patients with recurrent macular oedema were given further IRI as needed. Aqueous humour levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor (sVEGFR) and other cytokines/inflammatory factors were measured by the suspension array method. Aqueous flare values were measured with a laser flare metre and macular oedema was examined by optical coherence tomography. RESULTS: There were significant correlations between the aqueous flare and the aqueous levels of sVEGFR-1, placental growth factor, monocyte chemoattractant protein 1, soluble intercellular adhesion molecule-1, interleukin (IL)-6 and IL-8. There were also significant correlations between the change of the aqueous flare and improvement of central macular thickness after 1 month, after 6 months and at the 1st recurrence. Furthermore, a significant correlation was noted between the change of the aqueous flare and improvement of best-corrected visual acuity at 6 months after IRI, but not at 1 month or at the 1st recurrence. CONCLUSIONS: These findings suggest that the aqueous flare is associated with inflammatory factors/cytokines, and that the change of the aqueous flare value may influence the long-term prognosis in patients with BRVO receiving IRI therapy for macular oedema. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
BACKGROUND/AIMS: Correlations among functional-morphological parameters, the aqueous flare value (an indicator of inflammation) and aqueous humour levels of cytokines/inflammatory factors were investigated in patients with branch retinal vein occlusion (BRVO) and macular oedema who received intravitreal ranibizumab injection (IRI) and were followed for 6 months. METHODS: Aqueous humour levels of 11 cytokines or growth inflammatory/factors were measured in 45 patients with BRVO and macular oedema who received IRI. Patients with recurrent macular oedema were given further IRI as needed. Aqueous humour levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor (sVEGFR) and other cytokines/inflammatory factors were measured by the suspension array method. Aqueous flare values were measured with a laser flare metre and macular oedema was examined by optical coherence tomography. RESULTS: There were significant correlations between the aqueous flare and the aqueous levels of sVEGFR-1, placental growth factor, monocyte chemoattractant protein 1, soluble intercellular adhesion molecule-1, interleukin (IL)-6 and IL-8. There were also significant correlations between the change of the aqueous flare and improvement of central macular thickness after 1 month, after 6 months and at the 1st recurrence. Furthermore, a significant correlation was noted between the change of the aqueous flare and improvement of best-corrected visual acuity at 6 months after IRI, but not at 1 month or at the 1st recurrence. CONCLUSIONS: These findings suggest that the aqueous flare is associated with inflammatory factors/cytokines, and that the change of the aqueous flare value may influence the long-term prognosis in patients with BRVO receiving IRI therapy for macular oedema. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
Aqueous humour; Inflammation; Macula; Retina; Treatment Medical
Authors: Sruthi Arepalli; Charles C Wykoff; Joseph R Abraham; Leina Lunasco; Hannah Yu; Ming Hu; Sunil K Srivastava; Jamie L Reese; David Brown; Justis P Ehlers Journal: Eye (Lond) Date: 2022-10-11 Impact factor: 4.456
Authors: Alexander Aaronson; Claudia Taipale; Asaf Achiron; Vesa Aaltonen; Andrzej Grzybowski; Raimo Tuuminen Journal: Transl Vis Sci Technol Date: 2021-06-01 Impact factor: 3.283